By Anna Rose Welch, editor, Biosimilar Development
Sandoz's William Yoon and Sheila Frame reveal their expectations for the biosimilar industry, touching upon what education efforts are still needed and what trends in the broader pharmaceutical and healthcare market will be influential for future waves of biosimilar development and access.
The Further Consolidated Appropriations Act, 2020, signed into law on December 20, 2019, contains three provisions with implications for transition products. This article will review each of these three provisions — and their potential impact on sponsors — in further detail.
By Jon Lundqvist,GE Healthcare Life Sciences
Sometimes your size exclusion chromatography (SEC) results don’t look like you want them to. Fix issues such as poor resolution, peak tailing, and fronting with the tips in this FAQ.
Exclusive: Biosimilars Market Report
The laws establishing the U.S. biosimilar approval pathway were passed in 2010, but the market for biosimilars is only beginning to gain speed. How did the U.S. biosimilar market arrive at this point today? Where will it be in 2023 and 2025?